Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 25;12(7):651. doi: 10.1038/s41419-021-03926-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021, corrected publication 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — A Workflow of the analysis. Out of a total of 502,505 UK Biobank participants, 432,747 patients who contained genomic data were analysed. B Descriptive statistics of the UK Biobank cohort that was analysed. Either the number of participants in each category and their percentage with respect to the total cohort or the mean and standard deviation are shown. A full table of summary characteristics is available in Supplementary Table 3. C Table of the 15 SNPs in PARP1 present in our cohort. The SNP name (rsid), base position (bp), reference sequence (ref_seq), minor allele (minor) and minor allele frequencies are shown. This information was extracted from the NCBI database. D Odds ratios of the significant SNP in PARP1 associated with the risk of AD and their respective 95% confidence intervals. The odds ratios are calculated with respect to the allele shown in parentheses using individual binomial models that accounts for covariates. Only the significant SNPs are shown. Statistics of all 15 SNPs analysed are shown in Supplementary Table 4. E Genomic location of the PARP1 SNPs that are significantly associated with AD risk (VAR01 and VAR02) as well as sleepiness in AD (VAR03, explained in the next figure). F AD patients have a higher risk of sleepiness. β values with respect to the sleepiness score are calculated using a linear regression, after accounting for age, sex, social deprivation (Townsend deprivation score), education and obesity. Only the significant associations are shown. The numeric values of this model are in Supplementary Table 7. G β values of the model containing the significant SNP (rs2230484) that is associated with differences in sleepiness in the subset of patients with AD. Statistics of all 15 SNPs investigated are shown in Supplementary Table 8. H Theoretical impact of the SNP rs3219134 (T to C) on the gene-splicing efficiency. ESE Exonic Splicing Enhancers, ESS Exonic Splicing Silencer, EIE exon-identity elements.